Innovations in Prevention, Diagnosis, and Treatment of Cancer
Lymphoma and hemangiosarcoma are major health problems in Portuguese Water Dogs. This study collaborates with several top universities and researchers who are utilizing cutting edge technology to identify several regions of the genome that contain genetic, heritable, risk factors for lymphoma and hemangiosarcoma in Golden Retrievers. This information can then be applied to other breeds, including Portuguese Water Dogs. Tumor-specific mutations, when identified, can be clinically applied to reduce the incidence of these cancers, identify cancer earlier, and modify treatment plans to the individual patient.
Research Objective
Lymphoma and hemangiosarcoma are major health problems in Golden Retrievers, causing both suffering and premature death. Through ongoing collaboration, Drs. Jaime Modiano, Matthew Breen, and Kerstin Lindblad-Toh have identified several regions of the genome that contain genetic heritable risk factors for lymphoma and hemangiosarcoma in Golden Retrievers. They have tumor-specific mutations that occur recurrently in both cancers, some of which are linked to duration of remission when treated with standard of care. Their results indicate that a few heritable genetic risk factors account for as much as 50% of the risk for these cancers.
These findings offer the potential to develop tests and strategies for DNA tests that can predict risk for individual dogs, as well as to manage risk across the population as a whole. Indeed, both the inherited risk factors and tumor mutations point to pathways that have been implicated in the pathogenesis of lymphoma and hemangiosarcoma, and thus should inform the development of targeted therapies. In the current study, Drs. Modiano, Breen, and Lindblad-Toh will find the precise mutations for the heritable genetic risk factors and to validate markers (mutations) used to determine risk at the heritable loci in a larger independent population of Golden Retrievers from the United States and from Europe in order to develop robust risk prediction tools and an accompanying DNA test. Further, they will identify and characterize tumor mutations and study their relationship to the heritable risk factors, tumor pathogenetic mechanisms, and disease outcome.
Co-sponsored with the AKC Canine Health Foundation, Grant Number: 1889-G
Related News
Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR
RESEARCHERS
Dr. Jaime F Modiano, VMD PhD
University of Minnesota
Matthew Breen, PhD, CBiol, FSB
North Carolina State University